Descripción del proyecto
Un procesador tisular innovador para un diagnóstico rápido
El procesamiento de tejidos es un trabajo laborioso que dura hasta veinticuatro horas y emplea productos químicos nocivos. El objetivo principal del proyecto financiado con fondos europeos Origin es comercializar un dispositivo innovador que reduce el número de pasos de procesamiento y los productos químicos empleados. Además, los residuos químicos se pueden eliminar de una forma respetuosa con el medio ambiente y el funcionamiento del dispositivo es menos costoso. El proyecto llevará a cabo las actividades pertinentes para validar y optimizar aún más el dispositivo más allá de la fase de prototipo a fin de ofrecer un diagnóstico y unos resultados más rápidos en un entorno clínico.
Objetivo
Current tissue processors on the market take up to 24 hours to process samples for diagnosis and leave the operator exposed to chemical fumes. They also use different kinds of chemicals, in large volumes, which leads to cross contamination of chemicals and samples. This results in more plastic packaging to dispose of, making the process both costly and environmental unfriendly. Our company, DIAPATH SpA, is developing an innovative solution to these problems - the E-Processor. DIAPATH has been in the tissue processing industry since 1997 and currently has a turnover of €12Million and 100 employees. The E-Processor reduces the number of processing steps, and reduces the number of chemicals used. The operator will be safeguarded from chemical fumes and chemical containers will now be disposed of in a safe and environmentally friendly way. Our value proposition is, less operating costs due to reduced chemicals and packaging, faster diagnosis and results for patients. Our target users are Hospitals and Diagnostics Laboratories. The current global diagnostics market is estimated at €243.59 Million and expected to reach €378 Million by year 2025. Our entry point for our innovation will be the European market, where we already have significant market share. We will be using our extensive distribution chain to bring our innovation to international markets. Our innovation is currently at prototype stage with a compact functional machine. Further validation and tests remain to be done to bring it to market. The purpose of the phase 1 is to carry out feasibility studies before commercialisation. This will allow us to come up with a detailed business plan covering a projected five-year period. This innovation will grow our market share from 30% and increase our turnover to €50million by 2023. It will also create 15 new jobs.
Ámbito científico
- engineering and technologyenvironmental engineeringwaste management
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesclinical medicineoncology
- natural scienceschemical sciencesorganic chemistryalcohols
- natural sciencescomputer and information sciencesartificial intelligencemachine learningdeep learning
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
24057 Martinengo (Bg)
Italia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.